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Abstract
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Purpose—To examine associations between phthalate metabolite urinary concentrations during
early pregnancy and blood glucose levels obtained at the time of screening for gestational diabetes
mellitus (GDM).
Methods—Upon initiation of prenatal care, women with a mean gestational age of 12.8 weeks
were recruited for a study of environmental chemical exposures (n = 110) and provided a spot
urinary specimen. Blood glucose concentrations (mg/dl) were obtained from the electronic
medical record for those patients who did not experience a pregnancy loss and did not transfer
care to another facility prior to glucose screening (n = 72). Urinary concentrations of nine
phthalate metabolites and creatinine were measured at the US Centers for Disease Control and
Prevention. Associations between tertiles of phthalate metabolites concentrations and blood
glucose levels were estimated using linear regression.
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Results—Compared to pregnant women in the lowest concentration tertile, women with the
highest urinary concentrations (≥3rd tertile) of mono-iso-butyl phthalate (tertile: ≥15.3 μg/l, β =
−18.3, 95% CI: −35.4, −1.2) and monobenzyl phthalate (tertile: ≥30.3 μg/l, β = −17.3, 95% CI:
−34.1, −0.4) had lower blood glucose levels at the time of GDM screening after adjustment for
urinary creatinine and demographic covariates.
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Conclusion—Because maternal glucose levels increase during pregnancy to provide adequate
nutrition for fetal growth and development, these findings may have implications for fetal health.
However, given the limitations of our study, findings should be interpreted cautiously.
Keywords
Phthalate; Pregnancy; Blood glucose
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Widespread exposure to endocrine disrupting chemicals such as phthalates has led to
growing concerns about potential associations with adverse health effects. Phthalates, the
diesters of 1,2-benzenedicarboxylic acid, are a group of synthetic chemicals that are
ubiquitous in the environment because of their wide array of industrial applications
(Graham, 1973). Phthalates impart plastics with flexibility and are found in many products
such as cosmetics, automotive plastics and personal care products. Phthalates may also be
found in food packaging materials. High molecular weight (HMW) phthalates (≥250 Da),
such as di(2-ethylhexyl) phthalate (DEHP) are primarily used in the manufacture of flexible
vinyl and can be found in flooring, medical devices and consumer products. Low molecular
weight (LMW) phthalates (<250 Da) comprise metabolites of diethyl phthalate and dibutyl
phthalates (DBP). These phthalates are commonly found in personal care products and are
used in the making of lacquers, varnishes and in the coatings of medications (Graham,
1973). Dietary intake of contaminated food, dermal contact and inhalation are potential
pathways of exposure to phthalates in the general population (Hauser and Calafat, 2005;
Schettler, 2006). Upon exposure, phthalates undergo phase I and phase II transformations
into their biologically active monoester metabolites which are excreted in urine and can be
measured to estimate phthalate exposure in human populations (Frederiksen et al., 2007;
Wittassek and Angerer, 2008).
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Certain phthalates have anti-androgenic properties and can activate peroxisome proliferator
activated receptors (PPAR), properties that have led researchers to suspect that phthalate
exposure can impact energy balance and metabolism (Desvergne et al., 2009; Grun and
Bloomberg, 2009). Experimental studies in rats have shown that diets supplemented with
DEHP can induce glucose intolerance (Martinelli et al., 2006; Mushtaq et al., 1980),
decrease blood insulin and increase blood glucose levels (Gayathri et al., 2004). Although
limited in number, several cross-sectional studies that include adult men (Stahlhut et al.,
2007), adult women (Svensson et al., 2011), and lactating women (Hines et al., 2009)
support associations between phthalate metabolite urinary concentrations, insulin resistance
and diabetes mellitus. Widespread phthalate exposure and its potential for substantial public
health impact have led to studies that describe exposure among vulnerable subgroups such
as pregnant women and women of reproductive age (Adibi et al., 2008; Braun et al., 2013;
Peck et al., 2010). While there is concern about the endocrine disrupting properties of
phthalates, studies have yet to examine whether phthalate exposure during pregnancy is
associated with metabolic endpoints such as blood glucose levels. Pregnancy naturally
induces an insulin-resistant state in order to direct maternal metabolism to provide enough
nutrition to support the growth and development of the fetus. This insulin-resistant state
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results in higher circulating levels of glucose. An insufficient pancreatic insulin response to
lower blood glucose into the normal range can lead to gestational diabetes mellitus (GDM)
(Ryan, 2003).
Given emerging evidence that phthalates may disrupt insulin or glucose action in human
populations (Hauser and Calafat, 2005), we examined whether phthalate exposure is
associated with blood glucose alterations during pregnancy, a window when both maternal
and fetal health are susceptible to changes in glucose action or uptake. We evaluated this
hypothesis by measuring urinary concentrations of phthalate metabolites during early
pregnancy and examining associations with blood glucose levels obtained at the time of
prenatal GDM screening.

Materials and methods
Author Manuscript

Study population
Pregnant women (n = 110) were recruited for a pilot study of environmental chemical
exposures during their first prenatal care visit at the University of Oklahoma Medical Center
Women's Clinic between February and June 2008. Women were eligible to participate in the
study if their first prenatal care visit occurred before the 22nd week of pregnancy, they were
18 years of age or older, and spoke either English or Spanish. Women were ineligible to
participate if at the time of enrollment they presented with a medically threatened
pregnancy, multiple gestation, or if they had a history of diabetes (type 1 or type 2),
preeclampsia, preterm rupture of membranes, or preterm labor.
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For purposes of this analysis, women were excluded if they reported having a history of
gestational diabetes (n = 6). Patients were administered a one hour 50 g oral glucose
challenge test as part of routine GDM screening (median gestational age at screen: 26.3
weeks; range: 10.3–35.4 weeks). Blood glucose concentrations (mg/dl) were obtained from
the electronic medical record. Pregnant women with an elevated screening value of ≥135
mg/dl received further testing (oral glucose tolerance tests) for diagnosis of GDM
(Carpenter and Coustan, 1982; Metzger and Coustan, 1998). Our analyses were restricted to
72 pregnant women for whom glucose challenge test results were available in the medical
record. Reasons for missing glucose challenge test results included experiencing a
pregnancy loss (n = 10), transferring care to another facility (n = 6) or not returning to the
clinic for prenatal care (n = 16) prior to GDM screening. The demographic characteristics of
women who were excluded from analyses did not statistically differ from women whose
data were available (Table 1).
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This study was approved by the University of Oklahoma Health Sciences Center
Institutional Review Board. The analysis of blinded specimens by the Centers for Disease
Control and Prevention (CDC) laboratory was determined not to constitute engagement in
human subjects research.
Biomarkers of phthalate exposure
Upon enrollment, women provided a urine spot sample to measure biomarkers of exposure
to environmental contaminants and cotinine. Sterile urine collection containers were
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provided by the CDC laboratory. Following collection, urine specimens were temporarily
refrigerated in the clinic, until they could be aliquotted for storage (−20 °C) at the end of
each recruitment day. After the enrollment period ended, in 2011, samples were shipped to
the CDC laboratory on dry ice.
Urinary concentrations of nine phthalate metabolites and creatinine were measured. The
metabolites and their respective parent diesters are listed in Appendix A. Phthalate
metabolites were measured using online solid phase extraction coupled with high
performance liquid chromatography isotope dilution tandem mass spectrometry as described
elsewhere (Kato et al., 2005). Creatinine was measured using an enzymatic reaction on a
Roche Hitachi 912 chemistry analyzer (Roche Hitachi, Basel Switzerland).

Author Manuscript

Limits of detection (LODs) ranged from 0.2 μg/l for monocarboxypropyl phthalate (MCPP)
to 1.2 μg/l for mono-2-ethylhexyl phthalate (MEHP). Reported concentrations, including the
LOD of monoethyl phthalate (MEP) and monobenzyl phthalate (MBzP), were multiplied by
0.66 and 0.72, respectively, to account for the purity of the analytical standards used
(Centers for Disease Control and Prevention National Center for Environmental Health
Divsion of Laboratory Sciences, 2012). All but three of the nine phthalate metabolites were
detectable in 100% of urine specimens analyzed. MBzP and MCPP were detectable in 98%
and 99% of urine specimens, respectively. MEHP, a metabolite of DEHP, was detectable in
78% of urine specimens. For statistical analysis, urinary concentrations of phthalate
metabolites below the LOD were converted by dividing the LOD by the square root of two
(Hornung and Reed, 1990).
Measurement of urinary cotinine

Author Manuscript

Using urine samples collected at enrollment, analysis of urinary cotinine was conducted by
Lab Stat International in Canada (www.labstat.com) using high resolution capillary-column
gas chromatography with split/splitless injection, a fused silica capillary column and a
nitrogen-phosphorus detector. The LOD for urinary cotinine was 1.0 μg/l.
Phthalate exposure variables
Phthalate metabolite concentrations, expressed as continuous variables, were not linearly
associated with blood glucose concentrations. Therefore, categorical exposure variables
were created using tertiles of urinary concentrations of each phthalate metabolite (i.e., <33rd
percentile, 33rd to <66th percentile, and ≥66th percentile). Values defining the 33rd and
66th percentiles are displayed in Table 2.
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Additional variables were created by summing the urinary concentrations of the metabolites
of DEHP (ΣDEHP), of DBP (ΣDBP), and by molecular weight of the parent compound
(low: ΣLMW or high: ΣHMW). ΣHMW included MBzP, MCPP and all DEHP metabolites.
ΣLMW included MEP, mono-n-butyl phthalate (MnBP) and mono-iso-butyl phthalate
(MiBP).
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Participants completed an enrollment interview that provided information on demographics,
reproductive and medical histories and lifestyle factors. Demographic factors included age,
race/ethnicity, annual household income and educational level. Self-reported pre-pregnancy
height (inches) and weight (pounds) were used to calculate pre-pregnancy body mass index
(BMI) in kg/m2 using the formula weight (lb)/[height (in)]2 × 703. Participants also reported
date of last menstrual period (LMP), and parity. Gestational age at enrollment (weeks) was
calculated by subtracting the date of LMP from the date of enrollment and dividing the
number of days by seven. Gestational age at screening was calculated by subtracting LMP
date from the date of the glucose challenge test. If a woman self-reported she was currently
smoking or had urinary cotinine concentrations ≥15 μg/l, she was defined as an active
smoker (Benowitz et al., 2009).

Author Manuscript

Statistical methods
Analyses were conducted using SAS version 9.1.3. Continuous and categorical
characteristics of the sample (n = 72) were summarized using descriptive statistics.
Geometric mean (GM) concentrations, 95% confidence intervals (CI) and distribution
percentiles of unadjusted urinary phthalate metabolite concentrations were calculated.
Multiple linear regression was used to assess the association between tertiles of urinary
concentrations of phthalate metabolites (μg/L) and blood glucose levels (mg/dl), while
controlling for potential confounders. We included creatinine concentrations as an
independent factor in all models to adjust for urinary dilution (Barr et al., 2005). We refer to
models adjusted only for urinary creatinine concentrations as crude models.

Author Manuscript

We examined confounding by comparing estimates of the crude and adjusted model
parameters (linear coefficients) for each exposure of interest. Each potential confounding
variable was added to the model until all possible combinations of confounding factors were
explored. Covariates were retained in the final models if controlling for the factor(s)
produced a >10% change in adjusted estimates for phthalate metabolites. Variables
evaluated as confounders included Hispanic race/ethnicity, having greater than a High
School degree, reporting an annual household income greater than or equal to $20,000,
being nulliparous or a current smoker as well as age, pre-pregnancy BMI, gestational age at
enrollment and glucose screening. Final models evaluating MiBP were adjusted for race/
ethnicity. Models evaluating ΣLMW were adjusted for race/ethnicity and BMI. All other
models were adjusted for race/ethnicity and gestational age at enrollment.
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Results
The women retained in our analytic cohort were similar in demographic and clinical
characteristics when compared to those that were excluded from analyses (Table 1). The
majority of pregnant women (n = 72) were younger than 25 years of age, non-Hispanic, had
a pre-pregnancy BMI classified as overweight or obese and had less than or equal to a High
School education. Lastly, 29% of women were active smokers (Table 1). The highest and
lowest urinary metabolite concentrations observed were for MEP (GM = 216.4 μg/L, 95%
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CI: 161.9, 289.4) and for MEHP (GM = 3.2 μg/L, 95% CI: 2.5, 4.1) and MCPP (GM = 3.7,
95% CI: 3.1, 4.6), respectively. The GM and distribution percentiles for phthalate urinary
concentrations are reported in Table 2.
We present crude and adjusted linear regression models of the association between blood
glucose levels and urinary phthalate metabolite concentrations in the 2nd and 3rd tertiles as
compared with the 1st tertile in Table 3. Pregnant women with urinary concentrations of
MiBP (β = −18.30 95% CI, −35.41 to −1.19) and MBzP (β = −17.26 95% CI, −34.12 to
−0.40) in the highest concentration tertile had mean blood glucose levels approximately 18
mg/dl lower when compared to those in the 1st tertile after adjustment for urinary creatinine,
race/ethnicity, and gestational age at enrollment (for MBzP).

Discussion
Author Manuscript

Certain phthalates can activate PPARs (Desvergne et al., 2009; Grun and Bloomberg, 2009;
Hurst and Waxman, 2003), receptors known to influence lipid and glucose homeostasis.
However, our findings showing inverse associations between urinary concentrations of
MiBP and MBzP and blood glucose levels during pregnancy do not suggest that phthalate
exposure is associated with insulin resistance and subsequently higher blood glucose levels.
Although not statistically significant, associations with blood glucose levels were in the
same direction for all but two of the remaining urinary metabolites examined.
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Our findings for MBzP are consistent with a cross-sectional study examining the
relationship between phthalate exposure and the prevalence of diabetes in 255 non-pregnant
women living in the northern states of Mexico (Baja California Norte, Chihuahua, Coahuila,
Durango, Nuevo León, Sonora, and Tamaulipas) (Svensson et al., 2011). In that study, the
odds of self-reported diabetes (type 1 or 2) were lower for each 1-standard deviation (SD)
unit increase in log creatinine-adjusted urinary concentrations of MBzP (OR = 0.73, 95% CI
0.55, 0.97), but not for MiBP (OR = 0.94, 95% CI 0.62, 1.43). In contrast to our findings,
the odds of self-reported diabetes were higher with increasing levels of urinary
concentrations for individual DEHP metabolites (except MEHP) and for ΣDEHP (OR =
1.66 (1.01–2.73). These discrepencies may be due to differences in characteristics between
source populations.
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There are several methodological considerations that need to be taken into account when
interpreting our results. The pilot and exploratory nature of this study did not allow us to
explore the associations between maternal urinary phthalate levels and health and/or
developmental outcomes. While the majority of participants were screened between 24 and
28 weeks gestation as is typically recommended in the US, eight (11%) and 23 women
(32%) women were screened at gestational ages before 24 weeks and after 28 weeks,
respectively. Pregnant women are naturally insulin resistant, which inherently affects
glucose levels (Ryan, 2003) and hence, limits the generalizability of our findings. Also,
since metabolic changes increase glucose levels during pregnancy to support fetal growth,
our findings may have more implications for fetal health as opposed to maternal health. We
assessed phthalate exposure approximately 15 weeks (range: 3.4–25.1 weeks) before blood
glucose levels were obtained. It is possible that phthalate exposure at that time was outside
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the etiologically relevant window for exposure during pregnancy. Alternatively, the
variability in phthalate metabolite concentrations may have hindered our ability to
accurately examine the associations of interest. In addition, while their characteristics did
not statistically differ from our study sample, data for a large proportion of women were
unavailable (n = 38 or 34%). Our small sample size (n = 72) limited precision, statistical
power and our ability to assess confounding. We also tested a large number of associations
and our statistically significant findings could be attributed to chance. However, the fact that
associations between blood glucose levels and phthalate metabolites were in the same
(inverse) direction (except for MEHP and MEP), suggests that our results are fairly robust.
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Phthalate exposure in this study was categorized from a single spot urine sample collected
approximately 15 weeks before the screening test. Thus, exposure misclassification is a
concern given that phthalates are metabolized quickly in humans, with half-lives less than
24 h (Frederiksen et al., 2007), and exposures are most likely episodic. Evidence from
studies examining the temporal variability of phthalate metabolites suggests that
measurements obtained from a single urine sample are relatively predictive of exposure over
a limited period of time (1–3 months) (Adibi et al., 2008; Cantonwine et al., 2014; Hauser
and Calafat, 2005; Hoppin et al., 2002; Irvin et al., 2010; Peck et al., 2010). This is
attributed to the fact that exposure to phthalates via consumer products, such as through the
use of personal care products, may be recurrent. In a study of phthalate variability during
pregnancy (Braun et al., 2012), Braun et al. reported the top tertile of trimester-specific
MBP, MBzP and MEP concentrations had moderate sensitivity (0.62–0.81) and specificity
(0.80–0.90) for classifying the highest exposure tertile based on an average of three samples
collected throughout pregnancy. However, Braun et al. also demonstrated that variability
was biomarker specific. The authors suggest that a single spot urine sample may be adequate
to classify MBP and MEP concentrations during pregnancy but more than one spot urine
sample may be necessary for MBzP and the metabolites of DEHP. While we learn a great
deal regarding the variability of phthalate metabolite concentrations during pregnancy from
Braun et al., the study population was of higher socioeconomic status, recruited before
pregnancy as they sought infertility treatment and were told that the study was examining
the health effects of phthalates and other environmental chemicals. The authors note that
these factors may have hindered the generalizability of their results and impacted
participants' behavior before and during pregnancy; accounting for some of the variability in
phthalate metabolite concentrations observed.
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Another study showed better reproducibility for urinary MBzP concentrations measured in
2–3 urine samples over a 6–8 week period among minority women living in New York City
than for other metabolites (mean interclass correlation coefficient = 0.64) (Adibi et al.,
2008). Of further relevance to categorical measures, when studies of phthalate variability
defined exposure tertiles using a single urine measurement and then calculated the geometric
mean concentrations of repeated samples (3–4 urine samples) from the individuals within
each tertile, the geometric mean values were consistently lowest for those in the bottom
tertile and highest for those in the top tertile (Peck et al., 2010; Teitelbaum et al., 2008).
Thus, the use of a single urine sample to assess exposure in this cohort is expected to
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provide a reasonable indication of low, medium or high average phthalate exposure, but the
measure is not without error.
Despite these limitations, this study was the first to examine the association between blood
glucose levels and phthalate exposure in a sample of pregnant women. Large prospective
studies collecting several spot urine samples during pregnancy would provide useful
information to examine repeated measures of phthalate metabolite concentrations throughout
pregnancy in relation to metabolic endpoints, as well as the effect of various lag times.
Indeed, by investigating the etiologically relevant window of exposure before or during
pregnancy and taking intra-individual variability into account, such studies would contribute
to improved approaches for exposure assessment.
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Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
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BzBP

benzylbutyl phthalate

DEHP

di-2-ethylhexyl phthalate

DBP

dibutyl phthalates

DOP

di-n-octyl phthalate

GDM

gestational diabetes mellitus

MBzP

monobenzyl phthalate

MCPP

mono-3-carboxypropyl phthalate

MECPP

mono-2-ethyl-5-carboxypentyl phthalate

MEHP

mono-2-ethylhexyl phthalate

MEHHP

mono-2-ethyl-5-hydroxyhexyl phthalate

MEOHP

mono-2-ethyl-5-oxohexyl phthalate

MiBP

mono-iso-butyl phthalate

MEP

monoethyl phthalate

MnBP

mono-n-butyl phthalate

NHANES

National Health and Nutrition Examination Survey
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Demographic and clinical characteristics of obstetric cohort by inclusion status, Oklahoma, 2008.
Analytic cohort (n = 72)

Excludedb (n=38)

Characteristic
n

%

n

%

Hispanic

17

24

5

13

Non-Hispanic White

21

29

13

34

Non-Hispanic Black

27

37

16

42

Other

7

10

4

11

≤High school

47

65

19

50

>High school

25

35

19

50

≤ 19,999

53

74

29

76

≥$20,000

19

26

9

24

Nulliparous

19

26

8

21

Multiparous

53

74

30

79

Yes

21

29

12

32

No

51

71

26

68

15

21

-

Maternal race/ethnicity

Education level

Author Manuscript

Annual household income

Parity

Current smoker

Elevated GDM screen
Yes (≥135mg/dl)

-

Median (range)

Author Manuscript

Maternal age (years)

22 (18,38)

24

(18,38)

Prepregnancy body mass index (kg/m2)

26 (16, 47)

26

(16, 43)

Enrollment

12.8 (4.6, 22.0)

9.0

(4.0, 22.0)

At GDMa screen

26.3 (10.3,35.4)

-

-

14.8 (3.4, 25.1)

-

-

Gestational age (weeks)

Weeks from enrollment to GDMa screen
a

GDM, gestational diabetes mellitus.

b
Characteristics between excluded study participants and those retained in the analytical cohort did not differ statistically. P-values for chi-square
(categorical) or Wilcoxon rank sum tests (continuous) were not <0.05.
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Author Manuscript
63.53
589.07
251.69

ΣLMW

ΣHMW

ΣDEHP

ΣDBP

18.23
188.07

MBzP

3.73
216.42

33.28

MECPP

MEP

13.97

MEOHP

MCPP

3.24
19.88

MEHHP

11.22

MEHP

30.38

MiBP

GM

3.06–4.55

25.02–44.27

10.57–18.47

14.80–26.71

2.54–4.13

9.04–13.93

24.36–37.89

95% CI

132.83–370.56

278.12–900.01

49.06–78.01

78.89–298.89

13.24–25.10

161.86–289.37

Percentile

MnBP

Phthalate metabolite

59.48

148.18

23.05

36.82

8.50

92.07

2.35

16.90

7.70

10.35

1.40

6.65

16.35

25th

65.14

166.70

30.60

45.70

10.01

112.20

2.90

20.90

8.80

12.60

2.00

8.70

22.20

33rd

95.21

245.75

43.10

65.95

16.34

205.92

3.80

31.70

12.90

18.70

3.55

11.30

29.25

50th

138.30

433.26

63.70

101.30

30.31

343.20

5.70

47.10

20.40

29.60

5.20

15.30

43.30

66th

174.32

614.06

76.65

126.00

36.79

525.36

6.60

54.20

24.20

40.85

7.75

18.15

56.55

75th

Geometric means (GM), 95% confidence intervals (CI) and percentiles of phthalate metabolite urinary concentrations (μg/l) for the study population,
Oklahoma, 2008 (n = 72).
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−2.59
−0.17
−1.48
3.16

MECPP

MEP

MBzP

MCPP

3.82
−5.65
−1.39
1.76

ΣDEHP

ΣDBP

ΣLMW

ΣHMW
(−12.15, 15.66)

(−15.61, 12.83)

(−21.01, 9.70)

(−10.34, 17.98)

(−11.35, 17.67)

(−16.18, 13.21)

(−14.28, 13.94)

(−17.56, 12.38)

(−1.45, 26.10)

(−12.52, 16.17)

0.80

0.85

0.47

0.59

0.67

0.84

0.98

0.73

0.08

0.80

0.78

0.70

0.89

P-value

−12.98

−6.40

−8.54

−10.49

0.17

−9.84

−6.25

−4.30

−5.47

−8.94

1.23

−14.40

−13.11

β

Tertile 3a

(−29.42, 3.45)

(−22.06, 9.26)

(−26.09, 9.01)

(−26.79, 5.81)

(−16.31, 16.65)

(−27.47, 7.79)

(−21.08, 8.58)

(−20.33, 11.74)

(−21.25, 10.31)

(−25.71, 7.83)

(−14.02, 16.47)

(−32.27, 3.47)

(−31.15, 4.94)

95% CI

0.12

0.42

0.33

0.20

0.98

0.27

0.40

0.59

0.49

0.29

0.87

0.11

0.15

P-value

−0.27

−0.90

−7.88

3.82

0.72

−0.82

4.45

−2.95

11.06

2.59

7.73

−2.01

0.11

β

(−13.64, 13.11)

(−14.58, 12.79)

(−22.52, 6.76)

(−10.22, 17.86)

(−13.23, 14.68)

(−14.37, 12.73)

(−9.30, 18.19)

(−18.06, 12.17)

(−2.35, 24.47)

(−11.28, 16.46)

(−6.97, 22.43)

(−16.18, 12.17)

(−14.71, 14.93)

95% CI

Tertile 2a

Adjustedc

0.97

0.90

0.29

0.59

0.92

0.90

0.52

0.70

0.10

0.71

0.30

0.78

0.99

P-value

−14.23

−3.29

−11.73

−9.97

−1.19

−17.26

0.18

−3.26

−5.55

−9.65

9.07

−18.30

−15.61

β

Tertile 3a

(−30.71, 2.25)

(−19.34, 12.77)

(−28.57, 5.12)

(−27.11, 7.17)

(−17.09, 14.72)

(−34.12, −0.40)

(−14.57, 14.94)

(−20.38, 13.86)

(−21.77, 10.66)

(−27.19, 7.89)

(−6.30, 24.45)

(−35.41, −1.19)

(−32.99, 1.76)

95% CI

0.09

0.68

0.17

0.25

0.88

0.04

0.98

0.70

0.50

0.28

0.24

0.04

0.08

P-value

All models were adjusted for urinary creatinine. MnBP, MEHP, MEOHP, MEHHP, MECPP, MEP, MBzP, MCPP, ΣDEHP, ΣDBP and ΣHMW models were adjusted for gestational age at enrollment and
race/ethnicity. MiBP model was only adjusted for race/ethnicity. ΣLMW model adjusted for race/ethnicity and BMI.

c

12.32

MEHHP

(−12.94, 17.28)

Models adjusted for urinary creatinine.

b

1.83

MEOHP

Sum variables

2.17

MEHP

(−11.79, 17.38)

(−14.33, 16.45)

95% CI

The referent group is the 1st tertile.

a

2.80

DEHP

1.06

MiBP

β

Tertile 2a

Crudeb

Model

MnBP

DBP

Phthalate metabolite

Linear regression models assessing the association between blood glucose levels (mg/dl) and tertiles of urinary concentrations of phthalate metabolites
(μg/L), Oklahoma, 2008 (n = 72).
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